" class="no-js "lang="en-US"> Chris Torrance Archives - Medtech Alert
Friday, June 21, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

PhoreMost Expands into New Facility at Unity Campus, Cambridge, UK

PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, today announced […]

NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics

NeoCura Bio-Medical Technology Co., Ltd. (“NeoCura”), a leading RNA-based drug research and development company in […]

PhoreMost and POLARISqb Announce a Multi-target Collaboration to Investigate Next-generation Cancer Therapies

PhoreMost Limited, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more